Labcorp's New Reflex Test Hunts Hidden Hepatitis D Cases

Labcorp has launched a reflex testing solution for hepatitis D intended to identify patients with the most severe form of viral hepatitis earlier and close a gap in monitoring; shares (LH) traded at 335.69, down 1.08% on the day, as of 18:50 GMT on 25 August 2026.

Labcorp (ticker: LH) has launched a new hepatitis D test built as a reflex solution, aimed at surfacing patients carrying the most severe form of viral hepatitis earlier than routine practice currently manages. The company frames the launch as filling a monitoring gap: hepatitis D is rarely looked for, so it is rarely found, and patients often present only once liver damage has advanced.

The clinical logic behind a reflex design is straightforward. In a reflex workflow, an initial result automatically triggers a second, more specific test on the same sample, without the ordering physician having to remember to request it or the patient having to come back for another blood draw. That removes the two failure points that most often stop hepatitis D from being diagnosed at all: clinician awareness and patient follow-up.

Why hepatitis D slips through the net

Hepatitis D cannot establish itself on its own. It depends on hepatitis B to replicate, which means every hepatitis D patient is, by definition, already a hepatitis B patient. In practice, that dependency is exactly what makes the infection easy to miss. A patient who tests positive for hepatitis B is typically managed as a hepatitis B case, and unless someone specifically orders a further test, the coinfection stays invisible.

The consequence is a diagnostic population that is far smaller than the infected population. Clinicians and public health bodies have argued for years that hepatitis D is under-tested rather than uncommon, and that the patients most in need of specialist referral are the least likely to be identified. Labcorp's launch, reported by Fierce Biotech, is a direct attack on that structural problem: instead of relying on a physician to think of hepatitis D, the laboratory workflow raises the question itself.

That distinction matters commercially as well as clinically. A test that requires a doctor's specific request grows only as fast as awareness campaigns can travel. A reflex test grows with the volume of hepatitis B testing already flowing through the lab network — a much larger and more predictable base.

The commercial mechanics of a reflex launch

Reference laboratories make money on volume and on mix. Adding a specialty assay to an existing, high-volume front-end test improves both at once: the incremental sample handling cost is close to nothing because the specimen is already in the building, and the second test carries specialty pricing rather than routine pricing.

Labcorp has not disclosed pricing, reimbursement status or expected volumes for the new hepatitis D offering, and no revenue figure should be inferred from the launch. What can be said is where it sits strategically. Large diagnostics networks compete on menu breadth as much as on price: hospital systems, health plans and specialty hepatology practices consolidate their send-out testing with whichever laboratory can run the whole panel. Being the lab that automatically catches a hepatitis D coinfection is a reason for a hepatology clinic to route its hepatitis B work to that lab in the first place.

The rivalry with the other national reference laboratories runs along exactly this line. Neither Labcorp nor its competitors win specialty hepatology business on the routine chemistry panel; they win it on the hard-to-source assays layered on top. Hepatitis D, long treated as a niche, is being repositioned here as a standard adjunct to hepatitis B monitoring.

Where the shares sat on launch day

The market did not treat the announcement as a needle-mover. Labcorp changed hands at 335.69, down 1.08% from the previous close of 339.34, as of the last trade at 18:50 GMT on 25 August 2026. The day's range ran from 333.53 to 339.76, meaning the stock spent the session drifting toward the lower end rather than reacting to news.

That happened on a modestly positive tape. The S&P 500 tracker (SPY) was at $765.87, up 0.31% on the day against a previous close of $763.47. The Nasdaq 100 tracker (QQQ) sat at $710.61, up 0.61%, and the Dow 30 tracker (DIA) at $535.33, up 0.31%. So Labcorp was a laggard against all three benchmarks on the day of the launch — a reminder that single-assay additions, however clinically useful, do not usually register in a diagnostics company's valuation on day one.

Investors in reference labs tend to underwrite volume trends, payer mix and reimbursement rates rather than individual menu items. The relevant question for the shares is not whether this test is a good idea but whether the company can convert a series of specialty additions into a durable improvement in revenue per requisition.

What would make this launch count

Three things will show whether the reflex approach works as designed.

• Adoption by ordering systems. A reflex only fires if the health system's laboratory order sets are configured to allow it. Uptake among large hepatology practices and hospital networks is the practical gate.
• Reimbursement clarity. Reflex testing raises the question of who pays for the second test when the first was the one ordered. Payer policy will shape how freely clinicians allow the reflex to trigger.
• Referral into treatment. Finding patients only matters if the finding changes management. A rising diagnosed population strengthens the case for specialist referral pathways — and, over time, for the therapies aimed at this patient group.

There is a second-order effect worth watching. Drug developers working on hepatitis D have long complained that the diagnosed population is too small to run efficient trials or to build a commercial market. Diagnostics that widen identification make the therapeutic opportunity larger, which is why laboratory launches in neglected infectious diseases often precede rather than follow clinical investment.

The broader shift in laboratory strategy

The launch fits a pattern visible across the reference lab industry: moving away from being a commodity processor of routine panels and toward being the gatekeeper for specialty testing, where pricing holds up better and switching costs for customers are higher. Automation of the decision — reflex logic embedded in the workflow rather than left to clinician memory — is the mechanism.

For hepatitis D specifically, the test does not change the biology or the treatment landscape. What it changes is the probability that a patient with the most aggressive form of viral hepatitis is identified while intervention still helps. That is a public health argument first and a revenue argument second, but for a laboratory network, the two are not in conflict: the assays that clinicians come to expect as standard are precisely the ones that generate steady, recurring volume.

Key facts

• Company and share price: Labcorp (LH) at 335.69, -1.08% on the day, as of 18:50 GMT, 25 Aug 2026
• Product: New hepatitis D reflex test, launched to identify the most severe form of the virus earlier
• Problem addressed: A gap in hepatitis D monitoring, where coinfected patients are rarely tested and go undiagnosed
• Market backdrop: S&P 500 (SPY) +0.31% at $765.87 on the day of the launch; Labcorp lagged all three major benchmarks

Frequently asked questions

What is a reflex test?

A reflex test is a second, more specific laboratory test that is triggered automatically by the result of an initial test on the same sample. The ordering physician does not have to request it separately, and the patient does not have to return for another blood draw. It removes clinician memory and patient follow-up as barriers to diagnosis.

Why is hepatitis D considered the most severe form?

Hepatitis D depends on hepatitis B to replicate, so it only occurs in people already infected with hepatitis B. That coinfection is associated with a more aggressive disease course than hepatitis B alone, which is why identifying patients earlier matters clinically. Labcorp says its new test targets exactly this group.

How did Labcorp shares react to the launch?

Labcorp (LH) traded at 335.69 as of the last trade at 18:50 GMT on 25 August 2026, down 1.08% from the previous close of 339.34, with a day range of 333.53 to 339.76. That made it a laggard against the S&P 500, Nasdaq 100 and Dow 30 trackers, all of which were higher on the day.

How much revenue will the test generate for Labcorp?

No figure has been disclosed. Labcorp has not published pricing, reimbursement status or expected test volumes for the hepatitis D reflex offering, so any revenue estimate would be speculation. The commercial logic rests on layering specialty-priced testing onto existing high-volume hepatitis B samples already flowing through the lab.

Why does reflex testing matter for diagnostics companies commercially?

Because it links growth in a specialty assay to the volume of an existing routine test rather than to clinician awareness. The sample is already in the laboratory, so incremental handling cost is minimal, while the added test typically carries specialty rather than commodity pricing, improving revenue per requisition.

Could wider hepatitis D testing affect drug developers?

Potentially, yes. Companies working on hepatitis D therapies have long faced a small diagnosed population, which complicates trial recruitment and limits commercial scale. Diagnostics that identify more patients enlarge that pool, which is why laboratory launches in under-tested infectious diseases often precede therapeutic investment rather than following it.

Sources

• Labcorp launches new hepatitis D test to find patients with most severe form of virus — Fierce Biotech

Photo: https://kaboompics.com/ · Pexels Licence — source